Welcome to our dedicated page for China Dasheng Biotechnology Company news (Ticker: CDBT), a resource for investors and traders seeking the latest updates and insights on China Dasheng Biotechnology Company stock.
China Dasheng Biotechnology Co (CDBT) is a company engaged in the development and commercialization of new geometric configuration low carbon emission engines and other clean technology solutions. Recently, CDBT has terminated a consulting agreement with Kenneth Maciora, Empire Relations Group Inc., and Empire Holdings LLC due to failure to deliver work product. With a focus on reducing greenhouse emissions and improving efficiency, CDBT aims to create technologies that make a positive impact on the environment. The company has acquired Cycclone Magnetic Engines, Inc., a pioneering company in the clean technology industry with interests in transport operations in Australia.
FAQ
What is China Dasheng Biotechnology Co (CDBT) engaged in?
Why did CDBT terminate the consulting agreement with Kenneth Maciora?
What did CDBT acquire recently?
What is the main goal of CDBT's technology development?
Who is the CEO of CDBT?
What are the contact details for CDBT?
What is the focus of Cycclone Magnetic Engines, Inc.?
What are the key assets of Cycclone Magnetic Engines, Inc.?
What are the risk factors mentioned in the Safe Harbor Statement?